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ORIGINAL ARTICLE
Instrument-based Tests for Measuring Anterior
Chamber Cells in Uveitis: A Systematic Review
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ABSTRACT
Purpose: New instrument-based techniques for anterior chamber (AC) cell counting can offer automation and
objectivity above clinician assessment. This review aims to identify such instruments and its correlation with
clinician estimates.
Methods: Using standard systematic review methodology, we identiﬁed and tabulated the outcomes of studies
reporting reliability and correlation between instrument-based measurements and clinician AC cell grading.
Results: From 3470 studies, 6 reported correlation between an instrument-based AC cell count to clinician
grading. The two instruments were optical coherence tomography (OCT) and laser ﬂare-cell photometry
(LFCP). Correlation between clinician grading and LFCP was 0.66–0.87 and 0.06–0.97 between clinician grading
and OCT. OCT volume scans demonstrated correlation between 0.75 and 0.78. Line scans in the middle AC
demonstrated higher correlation (0.73–0.97) than in the inferior AC (0.06–0.56).
Conclusion: AC cell count by OCT and LFP can achieve high levels of correlation with clinician grading, whilst
offering additional advantages of speed, automation, and objectivity.
Keywords: Anterior chamber cells, aqueous humor, aqueous humour, diagnostic test, laser ﬂare-cell photo-
metry, optical coherence tomography, systematic review, uveitis
Uveitis, an umbrella term describing inﬂammatory
ocular conditions, is a signiﬁcant cause of blind-
ness worldwide.1–3 Anterior uveitis describes
inﬂammation affecting the anterior chamber (AC),
which is predominantly characterized by AC cells
and ﬂare, where disruption of the blood-aqueous
barrier results in leakage of inﬂammatory blood
constituents into the aqueous humor.
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Detection and monitoring of disease activity is cru-
cial for rationalizing medical therapy, which is parti-
cularly important because therapeutic interventions
for uveitis carry risks of signiﬁcant adverse ocular
and systemic side effects; these include cataract raised
intraocular pressure and opportunistic infection. The
Standardization of Uveitis Nomenclature (SUN)
Working Group proposed the now preferred clinical
AC cell grading system.4 In this, an observer aims
a 1 mm2 light beam through the AC and counts the
number of illuminated cells visible. The cell count is
then placed into one of six grades in the SUN grading
system (Table 1). Prior to SUN, a number of alterna-
tive systems existed that quantiﬁed cells in a similar
way.5–9
Multiple limitations of this system are recognized.
First, it is prone to bias due to reliance on subjective
estimation of an observer. Although instructions dic-
tate that cell counting should be carried out in one
moment in time, in reality, this is a near-impossible
task, especially at higher grades where cell counts
exceed 30–40 cells/mm2. Second, the SUN grading
system uses a non-linear, non-continuous scale with
large steps between grades. Changes in inﬂammatory
activity within one grade may go undetected, espe-
cially in the higher grades. Third, it relies upon the
presence of an ophthalmic clinician trained in slit-
lamp biomicroscopy, and therefore limits disease
monitoring to a hospital setting. Consequently, deliv-
ery of uveitis care in other health-care settings such as
remote screening and community-based monitoring
has not been feasible.
Instrument-based techniques such as laser ﬂare-cell
photometry (LFCP), and more recently anterior seg-
ment optical coherence tomography (AS-OCT), have
shown potential for objectively quantifying AC cells.
LFCP became available in 1988 and uses the light
scattering properties of AC particles to quantify the
concentration of inﬂammatory materials in the aqu-
eous humor. It has been primarily validated as a tool
for measuring AC ﬂare,10 the cloudy appearance
given to the aqueous during inﬂammation, however
several models also have the ability to count AC cells.
AS-OCT provides cross-sectional scans of the AC and
can capture cells in aqueous humor as hyper-
reﬂective dots. Given the drive towards objective,
quantitative assessment of disease status,
a systematic examination of the evidence for such
technologies is timely.11,12 This review aims to iden-
tify all instrument-based tools for counting AC cells
and evaluate their correlation with clinician grading
systems.
METHODS
This review was reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement.13 The methodology
was speciﬁed in advance and protocol registered
with PROSPERO (CRD42017084156).14,15
Eligibility Criteria
We included studies that described one or more instru-
ment-based methods for counting AC cells in patients
with uveitis (index tests) in comparison to a clinician
grading system (through slit-lamp examination). We
also included studies reporting test reliability (e.g.,
intra or inter-observer reliability and/or repeatability).
We did not place restrictions on age, gender, ethnicity,
underlying etiology or disease activity status. Animal
studies and studies involving only healthy partici-
pants, single case reports, commentaries, opinion arti-
cles, and pictorial articles were excluded.
The primary outcome was the level of correlation
between index tests and clinician grading. The sec-
ondary outcome was intra/inter-observer reliability
and repeatability of the index test.
Search Methods for Identifying Studies
We combined free text terms and index terms reﬂect-
ing the pathological ﬁnding of interest ‘cells’ and
‘anterior chamber’ or ‘aqueous humor’, and the dis-
ease context ‘uveitis’. The search strategy was
adapted to match the index terms in different
TABLE 1. Clinician grading scales used in each study.
Previously published grading systems Number of cells in each grade, by study
Grade SUN Hogan BenEzra Igbre Invernizzi Sharma Li Ohara Tugal-Tutkun
0 <1 0 <5 <1 <1 <1 0 0 <5
0.5 1–5 - - 1–5 1–5 1–5 1–5 1–4 -
1 6–15 5–10 5–10 6–15 6–15 6–15 6–10 5–10 5–10
2 16–25 10–20 11–20 16–25 16–25 16–25 11–20 11–30 11–20
3 26–50 21–50 21–50 26–50 26–50 26–50 21–50 31+ 21–50
4 50+ 50+ 50+ 50+ 50+ 50+ 50+ - 50+
5 - - hypopyon - - - - - hypopyon
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databases (supplementary materials). Database
searches were carried out in MEDLINE, Embase,
Cochrane Controlled Register of Trials (CENTRAL),
Centre for Reviews and Dissemination Database
(Health Technology Assessments and the Database
of Abstracts and Reviews of Effects), Clinicaltrials.
gov, WHO International Clinical Trials Registry
Platform (ICTRP portal), British Library’s ZETOC,
Conference Proceedings Citation Index (Web of
Science), British Library Ethos, ProQuest and
OpenGrey. We searched all databases from inception
to 22 March 2018, with no date or language restric-
tions. We manually searched citations of review arti-
cles and included studies to identify additional
relevant articles.
Study Selection
Two reviewers independently screened studies at
each stage. Disagreements were resolved through dis-
cussion and input from a third reviewer.
Data Collection
Two reviewers extracted data independently using a pre-
speciﬁed data extraction sheet. The data included popu-
lation characteristics (number of participants, gender,
age, underlying etiology), index test characteristics (tech-
nology, manufacturer, model, image acquisition settings,
area sampled and software automation), clinician grad-
ing (name of grading system used, number of patients in
each grade) and outcome (correlation coefﬁcient, inter/
intra-observer reliability). Cell counting analysis was
recorded as fully automated, semi-automated ormanual.
For the clinician grading, we extracted how each grade
was deﬁned and whether any modiﬁcations were made
to validated clinical grading systems.We contacted three
authors for further information16–18, all of whom
responded and one provided further data (conﬁdence
intervals) whichwas not reported in the original paper.16
Risk of Bias Assessment
Two reviewers independently assessed risk of bias
using the Quality Assessment of Diagnostic Accuracy
Studies tool (QUADAS-2).19 We adapted each element
in QUADAS-2 to address the review question.
Speciﬁcally, we explored potential sources of bias aris-
ing from the index test and clinician grading proce-
dures: whether the test protocols were determined
a priori and standardized for all participants, and
whether observers were blinded to test measurements.
Data Synthesis and Analysis
For each outcome, studies were grouped by index
test technology and then by choice of clinician grad-
ing tool. For each technology, we tabulated the
evidence and provided a narrative synthesis.
Where authors modiﬁed clinician grading systems,
these were considered separately from the validated
versions (Table 2). Where conﬁdence intervals for
correlation coefﬁcients were not reported, we esti-
mated them using sample size and correlation coef-
ﬁcient and presented this on a forest plot. All
statistical analysis was performed using Stata
Statistical Software (Release 15. College Station,
TX: StataCorp LP.)
RESULTS
Results of the Search
The study selection process is summarized in the
PRISMA ﬂow diagram (Figure 1). The searches from
database conception to 22 March 2018 yielded 3470
bibliographic records after de-duplication. Of these,
3432 were excluded upon screening of titles and
abstracts. The large number of exclusions is due to
the unrestrictive nature of our search strategy,
which did not specify any index test terms, and
the small number of published studies that made
comparisons between an index test and clinician
grading. The remaining 38 articles were obtained
in full text for further scrutiny and a further 32
articles were excluded. The reasons for exclusion
were missing or incomplete reporting of clinician
grading system (n = 13), the target disease not
being uveitis (n = 15) and no correlation/reliability
outcome reported (n = 4). Six unique studies met
the eligibility criteria and were included (Table 1).
Methodological Quality of the Included Studies
Using QUADAS-2, one study was identiﬁed as hav-
ing unclear risk of bias for patient selection due to
the exclusion of patients with posterior synechiae
(supplementary ﬁgure), which is known to affect
LFCP readings.20 Another study had an unclear
risk of bias in the index test domain as it was
unclear whether observers were blinded to the clin-
ician grading.21 One study had a high risk of poor
applicability due to patient selection, as only
patients with Behcet’s disease were included.20 We
graded all studies as having unclear risk of bias in
the reference test domain due to previously men-
tioned concerns around the reliability of subjective
clinician grading.
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Patients’ Characteristics and Design Features
The six studies enrolled 775 eyes (from 630 subjects) and
dated from 1989 to 2017.16–18,20–22 Participants were
recruited prospectively in all studies, except for Igbre
et al. who used existing clinical data. All comparisons
between index test and clinician grading were done in
a cross-sectional manner. Gender was reported in 5 out
of 6 studies, in which 47.8% (n = 301) participants were
male. The mean age was 45.2 years (range 27.0–81.0
years). Four studies included mixed etiologies, one
study did not report underlying etiology,16 and one
included only Behcet’s disease patients.20 The under-
lying etiologies across all studies included non-
granulomatous uveitis, sarcoidosis, HLA-B27-
associated uveitis, unspeciﬁed panuveitis, unspeciﬁed
intermediate uveitis, pars planitis, acute retinal necrosis,
granulomatous uveitis, juvenile idiopathic arthritis,
Behcet’s disease, multifocal choroiditis, sympathetic
ophthalmia, Vogt-Koyanagi-Harada disease, uveitis
glaucoma hyphema syndrome, birdshot chorioretino-
pathy, herpes simplex virus-associated uveitis, herpetic
keratouveitis, idiopathic uveitis and unknown cause.
Three studies included healthy controls,16,17,20 but only
analyses where uveitis patients separately reported
were included in the correlation analyses of this review.
Clinical Grading Systems
Three studies used the SUN grading system as a
comparator,16,18,22 one study used the scoring system
described by BenEzra et al. in 1991,9 one study used
a modiﬁed version of the 1959 Hogan system,5,17 and
one study used an unspeciﬁed clinical grading system.21
Upon contacting the author, the justiﬁcation for mod-
ifying the Hogan grading system was due to the uveitis
specialist’s preference.17 The differences between the
grading systems are outlined in Table 1. Four studies
reported the number of subjects with each clinical AC
cell grade,16–18,22 one study combined grades20 (for
example, “26 subjects had grades 0.5 to 2”) and one
did not report this.21 Sources of variation include num-
ber of cells seen in each grade (particularly in grades 1
and 2), the addition of a “0.5+” grade in the SUN grad-
ing system, the inclusion of a grade 5 to account for
presence of hypopyon by the BenEzra system, and the
lack of a speciﬁed slit beam size in the Hogan and
BenEzra systems (SUN grading speciﬁes 1 mm2).5,9
Instruments for Measuring AC Cells
Six studies were included for analysis.16–18,20–22 All
six studies compared the measurements of AC cells
on an instrument to a clinical grading system and
reported the correlation coefﬁcient. No studies
reported reliability for instrument-based grading.
We identiﬁed two instrument-based technologies
for quantifying AC cells: OCT and LFCP.
Optical Coherence Tomography
Four studies reported correlation between OCT and
a clinical grading system.16-18,22 Three studies16,18,22
used commercially available OCT machines and one
used a prototype system.17 The scanning protocols
(including the scan settings, position, area, and
volume scanned) were unique in each study. Li
et al. used a time-domain OCT system (Carl Zeiss
Meditec Inc., Dublin, CA), with an axial resolution of
17 microns and axial depth of 8 mm, to capture
concentric cross-sections of the central AC in 35 uvei-
tis patients (66 eyes). The Visante AS-OCT (Zeiss
Meditec Dublin, CA) was used by Igbre et al. to
capture 4–8 cross-sectional images in 41 patients (78
eyes), but the chamber position, area and volume
scanned were not reported.22 Sharma et al. captured
line scans and 6 mm3 scans at the central cornea
using the RTVue-100/CAM (Optovue) in 76 patients
(114 eyes).18 Invernizzi et al. used the swept source
Casia SS-1000 OCT device (Tomey Corporation,
Nagoya, Japan) to capture two 6 mm cross-sectional
scans of the AC in 167 uveitic eyes and 70 healthy
eyes.16 Two studies used manual cell counting16,22
and one automated this,17 whilst the fourth study
used both methods.18 For the two studies using auto-
mated cell counting, algorithms were developed de
novo for study purposes and are not openly
available.16,18
Laser Flare-Cell Photometry
Two studies reported correlation between LFCP and
a clinician grading system.20,21 In both studies, the
LFCPs were manufactured by KOWA (Kowa
Company, Tokyo, Japan), but the models differed;
FC-100020 and FC-2000.20 All ﬂare measurements
were calculated automatically using the machine’s
built-in function. As per the manufacturer’s recom-
mendations, the observer took several readings, dis-
carded the highest and lowest values, before
averaging the ﬁnal values to derive an average cell
count measurement and a standard deviation. Neither
study reported the position and area/volume of aqu-
eous scanned.
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Correlation between Index Tests and Clinician
Grading Systems
All six studies reported a correlation coefﬁcient
between the index test and a clinical grading system,
using Spearman’s r. The level of correlation between
index tests and clinician grading systems is shown
using a forest plot (Figure 2).
For the time-domain OCT devices, the correlations
were reported to be 0.74 (95% CI 0.62–0.83) in the
Visante device (Zeiss Meditec, Dublin, CA),22 and up
to 0.75 for the prototype Zeiss device, depending on
position of the scan17 (highest correlation r = 0.75 for
superior AC and lowest correlation r = 0.06 for infer-
ior AC). For the newer spectral-domain or swept
source OCT devices, which unlike the time domain
models, have a faster acquisition time and maximal
axial imaging resolution smaller than the normal
range of white cell width (10–17 microns),23 higher
correlation values were reported (0.97, p < .0001 for
RTVue-100/CAM, Optovue,18 and 0.94, p < .0001 for
the Casia SS-1000 OCT device, Tomey Corporation.16)
There was no apparent association between the level
of automation of OCT images analysis and the corre-
lation with AC cell count.
OCT can also acquire volume scans by repeating
densely placed single line scans. All four studies used
single line scans at different positions across the ante-
rior chamber. Sharma et al. additionally compared
single line scans to 3D cubic volume scans of 6 mm3,
and found the single line scans to have higher corre-
lation with the clinical grading than the volume scans
(0.94 for single line and 0.74–0.77 for volume scan).18
For the LFCP, two studies reported correlation
with clinician grading (r =0.6620 and r =0.8719). The
KOWA FC-2000, which scans a larger volume of
FIGURE 1. PRISMA ﬂow diagram.
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aqueous (0.5 mm3) than the FC-1000 (0.075 mm3),
achieved a higher level of correlation (r =0.8719).
Study Heterogeneity
There was considerable heterogeneity between the
methodology and populations described by the three
studies which shared a common comparator (SUN
grading).16,18,22 Due to the differences in scan acquisi-
tion parameters (varying sized scan areas and levels
of automation) and distribution of AC cell severity in
the study populations (as measured by clinician grad-
ing), we did not consider the index test measurements
to be directly comparable by meta-analysis.
DISCUSSION
This is the ﬁrst systematic review to evaluate instru-
ment-based technologies for counting AC cells in
uveitis. We found two technologies for this purpose:
OCT and LFCP.
When these technologies were used in a relatively
consistent way, with precisely speciﬁed measurement
and scanning protocols, we found strong correlation
with the SUN grading system (r = 0.74–0.97).
However, the range of correlation for instrument-
based measurements versus clinician grading ranged
from 0.06 to 0.97. Included studies demonstrated
a higher correlation coefﬁcient achieved by OCT
than LFCP. However, the inconsistent use of clinical
comparators across studies prevented us from making
direct comparisons between the technologies.
Performance and Limitations of Measures of
AC Cells
Studies of instrument-based cell counting using OCT
versus clinician grading reported correlations of r =
0.06–0.97, and for LFCP r = 0.66–0.87. The variation in
correlations seen between studies of the same plat-
form may arise due to several important factors
which may impact instrument-based measures only,
human clinical measures only, or both.
Factors Affecting Instrument-based Measures
Some variation in the correlation between studies
may suggest that not all instrument-based measures
of the same technology are equal, and that perfor-
mance may be affected by the model and technique
used. Newer models of OCT have higher resolution
(enabling improved discrimination of cells) and faster
acquisition time (overcoming the effects of missing or
double-counting moving cells).
Factors Affecting the Performance of Human-based Clinical
Measures
Some variation in the level of correlation may be
unrelated to the technology, but rather reﬂect poor
reliability of the clinician-based method. In addition
to the well-recognized generic limitations of subjectiv-
ity and imprecision,24,25 we noted some speciﬁc varia-
tions in choice of clinician grading systems used
across studies. Two studies published after the 2005
SUN Workshop used non-SUN grading systems,17,20
and one made a custom modiﬁcation by adding a 0.5
grade to the pre-SUN Hogan system.17 The reasons
for this are unclear. It is unlikely that preference for
one grading system over another is based on percep-
tions of superiority, as all clinical grading systems
share the same issues around subjectivity.
Additional factors that were not always recorded in
these studies but are known to impact the reliability
of the clinical measure are the experience of the clin-
ician, and number of observers independently scoring
each AC.25
Factors Affecting the Performance Of Both Instrument-based
and Human-based Measures
Factors such as patient selection may affect both
instrument-based and human measures. For exam-
ple, including patients with corneal opacity is
likely to reduce performance of both measures
due to reduced cell discrimination, although there
is some evidence it may impact OCT measures
less.26 Our review found higher levels of correla-
tion for scans involving a smaller area of the cen-
tral AC. This difference may arise from several
factors including:
Areas sampled: Li et al. reported weaker correla-
tion between clinical grading and OCT scans taken
in the inferior, compared to the middle or superior
AC. Li and colleagues suggested there may be an
unequal distribution of AC cells from the superior
to inferior parts of the AC, and a poorer correlation
when comparing the middle AC (captured by clin-
ician grading) and inferior AC (captured by OCT)
could be expected. They hypothesized that smaller
and lighter cells may be carried by the aqueous
circulation to superior parts of the AC, whereas
larger and heavier cells in the AC may accumulate
at the bottom.17
Acquisition time: Increased acquisition time may
allow ﬂoating AC cells to move through the aqu-
eous during successive raster scans resulting in
over- or under-counting of cells. Newer OCT mod-
els with higher acquisition speeds are unlikely to
be affected by this problem; however, time-domain
OCT models and various other operator and
patient factors (such as poor ﬁxation, opacities,
and reﬂections) may affect time required for scan
acquisition.
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Strengths and Limitations of the Review
The strength in this study lies in its systematic approach
of reviewing all publications of instrument-based tool
for AC cell countingwith clinician slit-lamp based grad-
ing system. Our search strategy was designed to have
high sensitivity for such studies and we searched
a broad range of databases, including conference pro-
ceedings, dissertation databases, and the grey literature.
Our limitations include the assumption that clinician
grading, the current gold standard, is an appropriate
reference standard for comparison. Our review cannot
answer the question of whether an instrument-based
measure is more accurate than clinician grading.
However, other advantages are apparent, including
capture of a larger area of AC and the ability to auto-
mate the cell counting process, whilst maintaining
a good correlation with the clinician-based method.
Limitations Due to Gaps in the Evidence
First, due to the small number of included studies and
heterogeneity in study design, it was not possible to
provide pooled estimates of correlation coefﬁcients. It
was also not possible to make direct comparisons
between OCT and LFCP due to the non-standardized
use of comparators. Second, there would be value in
evaluating the techniques across different subgroups to
ensure generalisability (i.e., subgroup analysis by dif-
ferent etiological groups, between active and inactive
disease and by age group and gender) but none of the
current studies reported enough subgroup data. Third,
imaging protocols for each study were variable. All
studies for OCT acquired line scans, however total
area of aqueous captured differed in each study. This
might not have been an issue had the number of cells
been reported per area/volume of aqueous. However,
all studies reported absolute total number of cells
observed. Future standardization of the output metrics
generated, including cell count per unit of aqueous, is
needed. This is essential for reliable comparison
between devices such as monitoring a patient over
time between different health settings, where multiple
devices may be used.
Clinical Relevance and Impact
This review found that instrument-based tools can
achieve high correlation with clinical grading. As dis-
cussed, earlier differences in design across studies
preclude reliable head-to-head comparison of the
two instrument-based techniques, but it is likely that
OCT will become the dominant technology for cell
counting as the LFCP models offering cell count
have been discontinued after the FC-2000. In addition,
OCT can be automated and performed without the
FIGURE 2. Forest plot of correlation coefﬁcients reported by all included studies between index test measurements versus clinician
grading, grouped by index test technology and clinician grading system.
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need for a skilled clinician. Implementing this tech-
nology in routine clinical care could potentially offer
more quantitative, objective, long-term monitoring of
anterior uveitis. These technologies could also permit
task-shifting away from a small number of clinical
experts to disease monitoring delivered by techni-
cians. This also carries implications for future care
delivery models, opening the possibility of remote
monitoring and community-based care.
Future studies should consider more explicit
reporting of patient, eye and ocular disease character-
istics to permit meaningful comparison of methods
and devices. Controlled studies, including healthy
individuals recruited from the full age range will
also be important to capture any non-pathological
changes in the permeability of the blood-aqueous
barrier, which develops with age. It will also be neces-
sary for devices to demonstrate discriminant validity,
correctly identifying AC cellular activity resulting
from uveitis, from red blood cells or pigmented iris
endothelial cells. Prospective longitudinal studies of
patients with quiescent and active inﬂammation are
needed to determine the minimum clinically impor-
tant difference and inform consensus around diagnos-
tic thresholds.27
Based on our review of the literature we would pro-
pose that key industry standards that need to be deﬁned
in order to support cross-device comparison include: (1)
unit of measurement (e.g., cells per mm3); (2) volume
and location within the AC that is sampled; (3) clear
reporting of any custom analysis software, including
image pre-processing, thresholds set for identifying
image features as cells (such as brightness of pixels),
discarding of spurious ﬁndings and the degree of man-
ual input required. In addition, all studies that seek to
validate such techniques should report: (1) population
characteristics (including disease etiology and distribu-
tion of disease severity within the cohort); (2) internal
validity measures (such as test–retest reliability and
inter/intra-rater reliability in the case of non-
automated techniques), and (3) conﬁdence intervals
for all reported performance metrics.
CONCLUSION
Instrument-based technologies such as OCT and LCFP
offer objectivity and automation to the assessment of
AC cells in uveitis, and in a controlled setting can
demonstrate high correlation with the current clinical
standard. OCT is likely to become the dominant tech-
nology for cell counting and is suitable for the wide-
scale deployment that would be necessary for it to
become the new standard. However, before this is pos-
sible, there is a need for consensus aroundmeasurement
standards for such instruments thatwould enable cross-
device comparison to support reliable longitudinal
measurement for patients in the real world.
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